Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Switch From Tenofovir to Raltegravir for Low Bone Mineral Density

Next Previous
Trial Profile

Switch From Tenofovir to Raltegravir for Low Bone Mineral Density

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Raltegravir (Primary)
  • Indications HIV infections
  • Focus Pharmacodynamics
  • Acronyms TROP

Most Recent Events

  • 15 Apr 2014 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 20 Jul 2011 Actual initiation date (Oct 2009) added as reported by ClinicalTrials.gov.
  • 20 Jul 2011 Planned end date changed from 1 Apr 2011 to 1 Oct 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top